Andrographolide is able to lower the expression levels of IFN-γ, IL-23, and IL-17A in the peripheral blood mononuclear cells (PBMCs) of patients with ulcerative colitis, increase the expression of IL-4, inhibit the Th1/Th17 immune response and promote the Th2 response (Zhu et al., 2018b). The gene discussed is IL17A; the disease is ulcerative colitis.